Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks

Tanya Lushchyk; Sankha Amarakoon; José P Martinez-Ciriano; L Ingeborgh van den Born; G Seerp Baarsma; Tom Missotten

doi:10.1111/aos.12119

Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks

Tanya Lushchyk, Sankha Amarakoon, José P Martinez-Ciriano, L Ingeborgh van den Born, G Seerp Baarsma, Tom Missotten

Research output: Contribution to journal › Article › Research › peer-review

Abstract

PURPOSE: Several clinical trials have established the efficacy of ranibizumab therapy administered every 4 weeks to treat exudative age-related macular degeneration (ARMD). Bevacizumab appears to be a cost-effective alternative to ranibizumab, although an optimal injection schedule has not yet been determined. In this study, we set out to determine whether bevacizumab treatment in exudative ARMD every 6 or 8 weeks is non-inferior to bevacizumab treatment every 4 weeks.

METHODS: A total of 191 patients with exudative ARMD were randomly assigned to a 1-year continuous regimen of intravitreal bevacizumab every 4 (n = 64), 6 (n = 63) or 8 weeks (n = 64). The primary outcome was visual acuity change after 1 year of treatment.

RESULTS: In all three treatment groups, visual acuity improved between baseline and 1 year. There was no statistically significant difference in the mean change of visual acuity score at 1 year for bevacizumab administered every 4 (1.96 ± 13.70), 6 (1.60 ± 10.98) or 8 weeks (5.98 ± 8.88). Reduction in central retinal thickness was observed in all three study groups. At 1 year, the mean decrease in central foveal thickness ranged from 86 ± 97 μm in the every 6 weeks group to 109 ± 90 μm in the group every 8 weeks group (p = 0.30).

CONCLUSION: At 1 year, bevacizumab administered every 6 or 8 weeks was not inferior to therapy administered every 4 weeks.

Original language	English
Pages (from-to)	e456-61
Journal	Acta Ophthalmologica
Volume	91
Issue number	6
DOIs	https://doi.org/10.1111/aos.12119
Publication status	Published - Sept 2013

Keywords

Aged
Aged, 80 and over
Angiogenesis Inhibitors/administration & dosage
Antibodies, Monoclonal, Humanized/administration & dosage
Bevacizumab
Drug Administration Schedule
Exudates and Transudates
Female
Fluorescein Angiography
Humans
Intravitreal Injections
Male
Prospective Studies
Tomography, Optical Coherence
Treatment Outcome
Vascular Endothelial Growth Factor A/antagonists & inhibitors
Visual Acuity/physiology
Wet Macular Degeneration/diagnosis

Access to Document

10.1111/aos.12119

Cite this

@article{a3b518bbb53742a89991c4fd259bb9b8,

title = "Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks",

abstract = "PURPOSE: Several clinical trials have established the efficacy of ranibizumab therapy administered every 4 weeks to treat exudative age-related macular degeneration (ARMD). Bevacizumab appears to be a cost-effective alternative to ranibizumab, although an optimal injection schedule has not yet been determined. In this study, we set out to determine whether bevacizumab treatment in exudative ARMD every 6 or 8 weeks is non-inferior to bevacizumab treatment every 4 weeks.METHODS: A total of 191 patients with exudative ARMD were randomly assigned to a 1-year continuous regimen of intravitreal bevacizumab every 4 (n = 64), 6 (n = 63) or 8 weeks (n = 64). The primary outcome was visual acuity change after 1 year of treatment.RESULTS: In all three treatment groups, visual acuity improved between baseline and 1 year. There was no statistically significant difference in the mean change of visual acuity score at 1 year for bevacizumab administered every 4 (1.96 ± 13.70), 6 (1.60 ± 10.98) or 8 weeks (5.98 ± 8.88). Reduction in central retinal thickness was observed in all three study groups. At 1 year, the mean decrease in central foveal thickness ranged from 86 ± 97 μm in the every 6 weeks group to 109 ± 90 μm in the group every 8 weeks group (p = 0.30).CONCLUSION: At 1 year, bevacizumab administered every 6 or 8 weeks was not inferior to therapy administered every 4 weeks.",

keywords = "Aged, Aged, 80 and over, Angiogenesis Inhibitors/administration & dosage, Antibodies, Monoclonal, Humanized/administration & dosage, Bevacizumab, Drug Administration Schedule, Exudates and Transudates, Female, Fluorescein Angiography, Humans, Intravitreal Injections, Male, Prospective Studies, Tomography, Optical Coherence, Treatment Outcome, Vascular Endothelial Growth Factor A/antagonists & inhibitors, Visual Acuity/physiology, Wet Macular Degeneration/diagnosis",

author = "Tanya Lushchyk and Sankha Amarakoon and Martinez-Ciriano, {Jos{\'e} P} and {van den Born}, {L Ingeborgh} and Baarsma, {G Seerp} and Tom Missotten",

note = "{\textcopyright} 2013 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.",

year = "2013",

month = sep,

doi = "10.1111/aos.12119",

language = "English",

volume = "91",

pages = "e456--61",

number = "6",

}

TY - JOUR

T1 - Bevacizumab in age-related macular degeneration

T2 - a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks

AU - Lushchyk, Tanya

AU - Amarakoon, Sankha

AU - Martinez-Ciriano, José P

AU - van den Born, L Ingeborgh

AU - Baarsma, G Seerp

AU - Missotten, Tom

PY - 2013/9

Y1 - 2013/9

N2 - PURPOSE: Several clinical trials have established the efficacy of ranibizumab therapy administered every 4 weeks to treat exudative age-related macular degeneration (ARMD). Bevacizumab appears to be a cost-effective alternative to ranibizumab, although an optimal injection schedule has not yet been determined. In this study, we set out to determine whether bevacizumab treatment in exudative ARMD every 6 or 8 weeks is non-inferior to bevacizumab treatment every 4 weeks.METHODS: A total of 191 patients with exudative ARMD were randomly assigned to a 1-year continuous regimen of intravitreal bevacizumab every 4 (n = 64), 6 (n = 63) or 8 weeks (n = 64). The primary outcome was visual acuity change after 1 year of treatment.RESULTS: In all three treatment groups, visual acuity improved between baseline and 1 year. There was no statistically significant difference in the mean change of visual acuity score at 1 year for bevacizumab administered every 4 (1.96 ± 13.70), 6 (1.60 ± 10.98) or 8 weeks (5.98 ± 8.88). Reduction in central retinal thickness was observed in all three study groups. At 1 year, the mean decrease in central foveal thickness ranged from 86 ± 97 μm in the every 6 weeks group to 109 ± 90 μm in the group every 8 weeks group (p = 0.30).CONCLUSION: At 1 year, bevacizumab administered every 6 or 8 weeks was not inferior to therapy administered every 4 weeks.

AB - PURPOSE: Several clinical trials have established the efficacy of ranibizumab therapy administered every 4 weeks to treat exudative age-related macular degeneration (ARMD). Bevacizumab appears to be a cost-effective alternative to ranibizumab, although an optimal injection schedule has not yet been determined. In this study, we set out to determine whether bevacizumab treatment in exudative ARMD every 6 or 8 weeks is non-inferior to bevacizumab treatment every 4 weeks.METHODS: A total of 191 patients with exudative ARMD were randomly assigned to a 1-year continuous regimen of intravitreal bevacizumab every 4 (n = 64), 6 (n = 63) or 8 weeks (n = 64). The primary outcome was visual acuity change after 1 year of treatment.RESULTS: In all three treatment groups, visual acuity improved between baseline and 1 year. There was no statistically significant difference in the mean change of visual acuity score at 1 year for bevacizumab administered every 4 (1.96 ± 13.70), 6 (1.60 ± 10.98) or 8 weeks (5.98 ± 8.88). Reduction in central retinal thickness was observed in all three study groups. At 1 year, the mean decrease in central foveal thickness ranged from 86 ± 97 μm in the every 6 weeks group to 109 ± 90 μm in the group every 8 weeks group (p = 0.30).CONCLUSION: At 1 year, bevacizumab administered every 6 or 8 weeks was not inferior to therapy administered every 4 weeks.

KW - Aged

KW - Aged, 80 and over

KW - Angiogenesis Inhibitors/administration & dosage

KW - Antibodies, Monoclonal, Humanized/administration & dosage

KW - Bevacizumab

KW - Drug Administration Schedule

KW - Exudates and Transudates

KW - Female

KW - Fluorescein Angiography

KW - Humans

KW - Intravitreal Injections

KW - Male

KW - Prospective Studies

KW - Tomography, Optical Coherence

KW - Treatment Outcome

KW - Vascular Endothelial Growth Factor A/antagonists & inhibitors

KW - Visual Acuity/physiology

KW - Wet Macular Degeneration/diagnosis

U2 - 10.1111/aos.12119

DO - 10.1111/aos.12119

M3 - Article

C2 - 23773796

SN - 1755-375X

VL - 91

SP - e456-61

JO - Acta Ophthalmologica

JF - Acta Ophthalmologica

IS - 6

ER -

Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks

Abstract

Keywords

Access to Document

Fingerprint

Cite this